Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of cixutumumab and temsirolimus in
treating patients with locally advanced or metastatic cancer. Monoclonal antibodies, such as
cixutumumab, can block cancer growth in different ways. Some block the ability of cancer
cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing
substances to them. Temsirolimus may stop the growth of cancer cells by blocking some of the
enzymes needed for cell growth. Giving cixutumumab together with temsirolimus may kill more
cancer cells.